US20040109889A1 - Surface treatment composition for soft substrates - Google Patents

Surface treatment composition for soft substrates Download PDF

Info

Publication number
US20040109889A1
US20040109889A1 US10/309,730 US30973002A US2004109889A1 US 20040109889 A1 US20040109889 A1 US 20040109889A1 US 30973002 A US30973002 A US 30973002A US 2004109889 A1 US2004109889 A1 US 2004109889A1
Authority
US
United States
Prior art keywords
treated
pharmaceutical substrate
substrate
exterior surface
treatable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/309,730
Other languages
English (en)
Inventor
Frank Bunick
Feng Lin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johnson and Johnson Consumer Inc
Original Assignee
McNeil PPC Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by McNeil PPC Inc filed Critical McNeil PPC Inc
Priority to US10/309,730 priority Critical patent/US20040109889A1/en
Assigned to MCNEIL-PPC, INC. reassignment MCNEIL-PPC, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BUNICK, FRANK J., LIN, FENG
Priority to EP03257620A priority patent/EP1426042A1/en
Priority to CA2452074A priority patent/CA2452074C/en
Priority to BR0305412-8A priority patent/BR0305412A/pt
Priority to MXPA03011173A priority patent/MXPA03011173A/es
Priority to ARP030104476A priority patent/AR042299A1/es
Publication of US20040109889A1 publication Critical patent/US20040109889A1/en
Priority to US12/370,117 priority patent/US8173161B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Definitions

  • This invention relates to a surface treatment composition for soft substrates, and methods for preparing and applying the same.
  • Soft dosage forms are widely used in a variety of consumer products. For example, many soft confections have been marketed with commercial success due to consumer preference. Further, pharmaceutical manufacturers have also developed oral dosage forms that provide alternatives to the traditional, swallowable solid tablets. These alternative dosage forms, which for example include chewable or orally disintegrable tablets, are often easier and more convenient to administer, especially to pediatric and geriatric patients. Softer tablets are also advantageous for applications where it is desirable to provide for the topical availability of an active ingredient in the mouth or throat to provide either local effects or systemic absorption.
  • the dosage form is designed to disintegrate in the mouth without chewing. See, e.g., U.S. Pat. Nos. 5,464,632, 5,223,264 and 5,178,878. While these soft tablets advantageously disintegrate completely in the mouth prior to swallowing, they also have the disadvantage of being highly friable. Thus, this dosage form also requires costly specialized handling and packaging in order to prevent breakage.
  • Known methods for reducing the friability of soft chewable or disintegrable tablets include incorporation of low-melting materials in the tablet matrix.
  • PCT Application No. WO 93/13758 describes soft tablets comprising a meltable binder distributed throughout the tablet, which has been melted and solidified to improve the strength (e.g. hardness and friability) of the tablets.
  • U.S. Pat. No. 4,327,076 discloses a soft, breakage-resistant chewable tablet compressed from particles comprising a fatty material.
  • U.S. Pat. No. 6,258,381 describes a tablet made from a granular agglomerate comprising a mixture of at least one active ingredient and a binder.
  • Swallowable tablets are commonly coated with film coatings or polymeric coatings, such as those comprising cellulose derivatives, in order to improve their swallowability. These coatings typically surround the entire surface of the tablet.
  • the coatings typically employed for swallowable tablets are not particularly suitable for use on chewable tablets or those designed to disintegrate in the oral cavity because they would hinder the dissolution, disintegration, chewability, and organoleptic characteristics, such as mouthfeel of such soft tablets.
  • Typical manufacturing methods for these types of dosage forms include making a core, coating the core with impermeable material, then removing a portion of the core and coating to create the area for drug dissolution. See, e.g., U.S. Pat. No. 4,803,076 (tablet press for use in the manufacture of a truncated cone-shaped, as well as an apparatus for removal of a portion of the coated dosage form.).
  • a substantial level of coating is required in these types of controlled release applications in order for the coating to function as an impermeable barrier to the passage of water and/or active ingredient therethrough. Due to the dissolution rate designed for these tablets, such impermeable coatings are not only unsuitable for immediate release applications, but they are only intended for use on hard, swallowable tablets.
  • the present invention comprises, consists of, and/or consists essentially of a treated pharmaceutical substrate comprised of, consisting of, and/or consisting essentially of:
  • a soft pharmaceutical substrate having a hardness value of no more than about 15 kp/cm 2 and comprised of an exterior surface having an exterior surface area, said exterior surface comprised of at least one treatable surface;
  • said treated surface has a total surface area that is less than the total exterior surface area of the exterior surface, and the treated pharmaceutical substrate possesses a friability factor of at least about 2.
  • Another embodiment of the present invention is directed to a method for reducing the friability of a soft pharmaceutical substrate having a hardness value of no more than about 15 kp/cm 2 , said soft pharmaceutical substrate comprised of an exterior surface having at least one treatable surface, comprised of, consisting of, and/or consisting essentially of:
  • said treatable surface has a total surface area that is smaller than the total exterior surface area of the exterior surface, and the treated pharmaceutical substrate possesses a friability factor of at least about 2.
  • Yet another embodiment of the present invention is directed to a treated immediate-release pharmaceutical substrate comprised of, consisting of, and/or consisting essentially of:
  • a soft pharmaceutical substrate having a hardness value of no more than about 15 kp/cm 2 and comprised of an exterior surface having an exterior surface area, said exterior surface comprised of at least one treatable surface;
  • said treated surface has a total surface area that is smaller than the total exterior surface area of the exterior surface, and the treated pharmaceutical substrate possesses immediate release properties and a friability factor of at least about 2.
  • Yet another embodiment of the present invention is directed to a treated pharmaceutical substrate comprised of, consisting of, and/or consisting essentially of:
  • a soft pharmaceutical substrate having a hardness value of no more than about 15 kp/cm 2 and comprised of an exterior surface having an exterior surface area, said exterior surface comprised of at least one treatable surface;
  • the weight of said water dispersible polymer layer is not more than about 0.5% of the weight of the untreated substrate, and the treated pharmaceutical substrate possesses a friability factor of at least about 2.
  • the friability of the soft substrates treated in accordance with the present invention is significantly reduced without affecting their pleasant taste. Due to their reduction in friability, such treated soft substrates may be processed with standard bulk handling equipment and packaged in bottles.
  • FIG. 1A is an enlarged, perspective view of a flat-faced, round tablet.
  • FIG. 1B is an enlarged top plan view of the tablet of FIG. 1A., the bottom plan view being identical thereto;
  • FIG. 1C is an enlarged side view of the tablet of FIG. 1A.
  • FIG. 2A is an enlarged, perspective view of a flat-faced, squared tablet.
  • FIG. 2B is an enlarged top plan view of the tablet of FIG. 2A., the bottom plan view being identical thereto;
  • FIG. 2C is an enlarged side view of the tablet of FIG. 2A.
  • FIG. 3A is an enlarged, perspective view of a flat-faced, triangular tablet.
  • FIG. 3B is an enlarged top plan view of the tablet of FIG. 3A., the bottom plan view being identical thereto;
  • FIG. 3C is an enlarged side view of the tablet of FIG. 3A.
  • FIG. 4A is an enlarged, perspective view of a flat-faced, hexagonal tablet.
  • FIG. 4B is an enlarged top plan view of the tablet of FIG. 4A., the bottom plan view being identical thereto;
  • FIG. 4C is an enlarged side view of the tablet of FIG. 4A.
  • FIG. 5A is an enlarged, perspective view of a bi-convexed faced, round tablet having a ledge.
  • FIG. 5B is an enlarged top plan view of the tablet of FIG. 5A., the bottom plan view being identical thereto;
  • FIG. 5C is an enlarged side view of the tablet of FIG. 5A.
  • FIG. 5D is a further enlarged view of the land as illustrated in FIG. 5C.
  • FIG. 6A is an enlarged, perspective view of a bi-convexed faced, oblong caplet.
  • FIG. 6B is an enlarged top plan view of the caplet of FIG. 6A., the bottom plan view being identical thereto;
  • FIG. 6C is an enlarged side view of the caplet of FIG. 6A.
  • FIG. 7A is a perspective view of the tablet of FIG. 1A, having a polymeric dispersion application at both faces and both rims.
  • FIG. 7B is a perspective view of the tablet of FIG. 1A, having a polymeric dispersion application at the bellyband and both rims.
  • FIG. 7C is a perspective view of the tablet of FIG. A, having a polymeric dispersion application at the upper face and one-half of the upper rim, and at the lower face and one half of the lower rim (not shown).
  • FIG. 7D is a perspective view of the tablet of FIG. 1A, having a polymeric dispersion application at the bellyband, and at one-half of the upper rim and one-half of the lower rim.
  • FIG. 7E is a perspective view of the tablet of FIG. 1A, having a polymeric dispersion application at both rims.
  • FIG. 8A is an enlarged, cross-sectional view of a substrate having a polymeric layer residing upon at least a portion of its treatable surface.
  • FIG. 8B is an enlarged, cross-sectional view of a substrate having a polymeric layer residing at at least a portion of its treatable surface.
  • FIG. 8C is an enlarged, cross-sectional view of a substrate having a polymeric layer residing immediately beneath at least a portion of its treatable surface.
  • substrate refers to a surface, layer or underlying base or support upon which another substance resides or acts
  • vulnerable edge is any substrate edge, that is particularly susceptible to mechanical damage.
  • rim shall include a vulnerable edge on a substrate, which is defined during compaction (also referred to as “compression”) via a contact region between an upper or lower punch face and a die wall, and an overlap area.
  • overlap area shall mean a width of the substrate surface on either side of a vulnerable edge; although the size of the overlap area is not critical, it typically ranges from about 0 mm to about 2.0 mm, e.g.
  • the tablet possesses two rims 11 , 11 ′, each of which includes a vulnerable edge 18 and an overlap area 15 (shown in part), as well as four side vulnerable edges 12 (shown in part), each of which includes a vulnerable edge 17 and an overlap area 15 ′.
  • “belly band,” as used herein, shall mean a substrate surface 2 , that is defined during compaction via contact with a die wall and includes one-half of the overlap area of the upper rim 5 and one-half of the overlap area of the lower rim 5 ′.
  • “Face,” as used herein, is the portion 3 of a compressed tablet formed by the upper and lower punch faces, and includes one-half of the overlap area of a rim 5 ′′.
  • “land,” as used herein, is a planar substrate surface 43 , 43 ′ around the perimeter of a convex portion of a substrate face bearing one or more convex surfaces, and includes the rim 115 .
  • Treatable Surface shall mean any surface of the substrate that includes at least a portion of a vulnerable edge so long as the total treatable surface area is from about 10% to about 90% of the total substrate surface area. Examples of treatable surfaces include the rim, belly band, face, and/or the land, or portions thereof.
  • dosage form applies to any composition designed to contain a specific pre-determined amount (dose) of a certain ingredient, such as, for example, an active ingredient as defined below.
  • Suitable dosage forms include those suitable for oral administrations including, but not limited to, pharmaceutical drug delivery systems, or compositions for delivering minerals, vitamins and other nutraceuticals, oral care agents, flavorants, and the like.
  • immediate release shall mean that the dissolution of the active ingredient contained in the dosage form conforms to USP specifications for immediate release tablets containing the particular active ingredient employed.
  • USP 24 specifies that in pH 5.8 phosphate buffer, using USP apparatus 2 (paddles) at 50 rpm, at least 80% of the acetaminophen contained in the dosage form is released therefrom within 30 minutes after dosing
  • USP 24 specifies that in pH 7.2 phosphate buffer, using USP apparatus 2 (paddles) at 50 rpm, at least 80% of the ibuprofen contained in the dosage form is released therefrom within 60 minutes after dosing. See USP 24 , 2000 Version, 19-20 and 856 (1999).
  • the dosage form may be an orally administered system for delivering a pharmaceutical active ingredient to the gastro-intestinal tract of a human, or alternatively to the mouth or throat for localized activity, topical absorption, or systemic absorption through the oral, buccal, or pharyngeal mucosa.
  • the dosage form may be an orally administered “placebo” system consisting essentially of pharmaceutically inactive ingredients, which is designed to have the same visual appearance as a particular pharmaceutically active dosage form.
  • Placebo” system dosage forms are suitable for use as control dosage forms in clinical studies, and in particular, those studies designed for testing the safety and efficacy of a particular pharmaceutically active ingredient.
  • “Tablets,” as used herein, refer to compressed or molded solid dosage forms of any shape or size.
  • “Water soluble” or “water solubilize,” as used herein in connection with non-polymeric materials shall mean from sparingly soluble to very soluble, i.e., not more than 100 parts water required to dissolve 1 part of the non-polymeric, water soluble solute. See Remington, “The Science and Practice of Pharmacy,” pages 208-209 (2000).
  • “Water soluble” or “water solubilize,” as used herein in connection with polymeric materials shall mean that the polymer swells in water and can be dispersed at the molecular level to form a homogeneous dispersion or colloidal solution.
  • Water dispersible as used herein in connection with polymeric materials, shall mean at least a portion of the polymer is removed from the dosage form within 60 minutes after immersion of the dosage form in an aqueous medium such as that used for in-vitro dissolution testing, or gastrointestinal fluids.
  • Hardness indicates the resistance of the dosage form to breaking in response to a diametrically applied stress. Hardness is a term used in the art to describe the diametrical breaking strength as measured by the conventional pharmaceutical hardness testing equipment, such as a Vector-Schleuniger Hardness Tester. In order to compare values across different size tablets, the breaking strength is normalized for the area of the break, which may be approximated as (tablet diameter x thickness).
  • tablette tensile strength This normalized value, expressed in kp/cm 2 , is sometimes referred to in the art as “tablet tensile strength.”
  • tablette hardness testing is found in Leiberman et al., Pharmaceutical Dosage Forms—Tablets , Volume 2, 2 nd ed., Marcel Dekker Inc., 1990, pp. 213-217, 327-329, which is incorporated by reference herein.
  • the substrate of the present invention may be any edible solid or semi-solid composition having at least one vulnerable edge.
  • the substrate has one or more major faces.
  • Substrates suitable for use in the present invention may be of any size or shape.
  • the substrate may be in the shape of a truncated cone.
  • the substrate may be shaped as a polyhedron, such as a cube, pyramid, prism, or the like; or may have the geometry of a space figure with some non-flat faces, such as a cone, cylinder, sphere, torus, or the like.
  • Exemplary substrate shapes which may be employed include tablet shapes formed from compaction tooling shapes described by “The Elizabeth Companies Tablet Design Training Manual” (Elizabeth Carbide Die Co., Inc., p.7 (McKeesport, Pa.) (incorporated herein by reference) as follows (the tablet shape corresponds inversely to the shape of the compaction tooling):
  • FIGS. 1 - 6 Illustrative examples of some substrate shapes are shown in FIGS. 1 - 6 .
  • FIGS. 1A through 1C illustrate a flat-faced, round substrate 100 having an upper face 3 , a lower face (not shown), an upper rim 1 , a lower rim 1 ′, and a belly band 2 .
  • FIGS. 2A through 2C illustrate a squared, flat-faced substrate 200 having an upper face 13 , a lower face (not shown), a four-sided bellyband 7 (not all sides shown), four side vulnerable edges 12 , an upper rim 11 , and lower rim 11 ′.
  • Each of the side vulnerable edges includes a vulnerable edge 17 and an overlap area 15 ′ on each of the two adjacent bellyband sides.
  • FIGS. 1A through 1C illustrate a flat-faced, round substrate 100 having an upper face 3 , a lower face (not shown), an upper rim 1 , a lower rim 1 ′, and a belly band 2 .
  • FIGS. 4A through 4C illustrate a triangular, flat-faced substrate 300 having an upper face 23 (one side shown), a lower face (not shown), a three-sided bellyband 27 (not all sides shown), an upper rim 21 , a lower rim 21 ′, and three side vulnerable edges 22 .
  • Each of the side vulnerable edges includes a vulnerable edge 22 ′ and an overlap area 25 on each of the two adjacent bellyband sides.
  • FIGS. 4A through 4C illustrate a hexagonal, flat-faced substrate having an upper face 33 , lower face (not shown), a six-sided bellyband 37 (not all sides shown), upper rim 31 , lower rim 31 ′, and six vulnerable side edges 32 .
  • FIGS. 5A through 5D illustrate a bi-convex, round substrate 500 having an upper face 44 , lower face, 44 ′, upper rim 41 ′, lower rim 41 ′′, bellyband 42 , an upper land 43 ′, and lower land 43 ′′.
  • FIGS. 6A through 6C illustrate an oblong convex substrate 600 having two oppositely positioned convex faces 155 , 155 ′, and a bellyband 160 therebetween (shown most clearly in FIGS. 6A and 6C).
  • the substrate 600 has an upper land 430 , a lower land 430 ′, an upper rim 210 , and a lower rim 210 ′.
  • Substrates suitable for use in the present invention may contain one or more active ingredients.
  • active ingredient is used herein in a broad sense and may encompass any material that can be carried by or entrained in the system.
  • the active ingredient can be a pharmaceutical, nutraceutical, vitamin, dietary supplement, nutrient, herb, foodstuff, dyestuff, nutritional, mineral, supplement, oral care agent or favoring agent or the like and combinations thereof.
  • Suitable oral care agents include breath fresheners, tooth whiteners, antimicrobial agents, tooth mineralizers, tooth decay inhibitors, topical anesthetics, mucoprotectants, and the like.
  • Suitable flavoring agents include menthol, peppermint, mint flavors, fruit flavors, chocolate, vanilla, bubblegum flavors, coffee flavors, liqueur flavors and combinations and the like.
  • Suitable pharmaceutical active ingredients useful herein can be selected from classes from those in the following therapeutic categories: ace-inhibitors; alkaloids; antacids; analgesics; anabolic agents; anti-anginal drugs; anti-allergy agents; anti-arrhythmia agents; antiasthmatics; antibiotics; anticholesterolemics; anticonvulsants; anticoagulants; antidepressants; antidiarrheal preparations; anti-emetics; antihistamines; antihypertensives; anti-infectives; anti-inflammatories; antilipid agents; antimanics; anti-migraine agents; antinauseants; antipsychotics; antistroke agents; antithyroid preparations; anabolic drugs; antiobesity agents; antiparasitics; antipsychotics; antipyretics; antispasmodics; antithrombotics; antitumor agents; antitussives; antiulcer agents; anti-uricemic agents; anxiolytic
  • the active ingredient may be selected from the group of pharmaceuticals consisting of analgesics, anti-inflammatory agents, antiarthritics, anesthetics, antihistamines, antitussives, antibiotics, anti-infective agents, antivirals, anticoagulants, antidepressants, antidiabetic agents, antiemetics, antiflatulents, antifungals, antispasmodics, appetite suppressants, bronchodilators, cardiovascular agents, central nervous system agents, central nervous system stimulants, decongestants, diuretics, expectorants, gastrointestinal agents, migraine preparations, motion sickness products, mucolytics, muscle relaxants, osteoporosis preparations, polydimethylsiloxanes, respiratory agents, sleep-aids, urinary tract agents and mixtures thereof.
  • analgesics consisting of analgesics, anti-inflammatory agents, antiarthritics, anesthetics, antihistamines, antitussives, antibiotics, anti-infective agents, antivirals
  • Suitable polydimethylsiloxanes which include, but are not limited to dimethicone and simethicone, are those disclosed in U.S. Pat. Nos. 4,906,478, 5,275,822, and 6,103,260, the contents of each is expressly incorporated herein by reference.
  • simethicone refers to the broader class of polydimethylsiloxanes, including but not limited to simethicone and dimethicone.
  • Suitable gastrointestinal agents include antacids such as calcium carbonate, magnesium hydroxide, magnesium oxide, magnesium carbonate, aluminum hydroxide, sodium bicarbonate, dihydroxyaluminum sodium carbonate; stimulant laxatives, such as bisacodyl, cascara sagrada, danthron, senna, phenolphthalein, aloe, castor oil, ricinoleic acid, and dehydrocholic acid, and mixtures thereof; H2 receptor antagonists, such as famotadine, ranitidine, cimetadine, nizatidine; proton pump inhibitors such as omeprazole or lansoprazole; gastrointestinal cytoprotectives, such as sucraflate and misoprostol; gastrointestinal prokinetics, such as prucalopride, antibiotics for H.
  • antacids such as calcium carbonate, magnesium hydroxide, magnesium oxide, magnesium carbonate, aluminum hydroxide, sodium bicarbonate, dihydroxyaluminum
  • pylori such as clarithromycin, amoxicillin, tetracycline, and metronidazole
  • antidiarrheals such as diphenoxylate and loperamide
  • glycopyrrolate such as glycopyrrolate
  • antiemetics such as ondansetron
  • analgesics such as mesalamine.
  • the gastrointestinal agents may be selected from bisacodyl, famotadine, ranitidine, cimetidine, prucalopride, diphenoxylate, loperamide, lactase, mesalamine, bismuth, antacids, and pharmaceutically acceptable salts, esters, isomers, and mixtures thereof.
  • the active ingredient is selected from analgesics, anti-inflammatories, and antipyretics, which included but are not limited to non-steroidal anti-inflammatory drugs (NSAIDs) including: 1) propionic acid derivatives, i.e., e.g. ibuprofen, naproxen, and ketoprofen; 2) acetic acid derivatives, i.e., e.g. indomethacin, diclofenac, sulindac, and tolmetin; 3) fenamic acid derivatives, i.e., e.g.
  • NSAIDs non-steroidal anti-inflammatory drugs
  • oxicams i.e., e.g. piroxicam, sudoxicam, isoxicam, and meloxicam.
  • the active ingredient is a propionic acid derivative NSAID selected from ibuprofen, naproxen, flurbiprofen, fenbufen, fenoprofen, indoprofen, ketoprofen, fluprofen, pirprofen, carprofen, oxaprozin, pranoprofen, suprofen, and pharmaceutically acceptable salts, derivatives, and combinations thereof.
  • NSAID selected from ibuprofen, naproxen, flurbiprofen, fenbufen, fenoprofen, indoprofen, ketoprofen, fluprofen, pirprofen, carprofen, oxaprozin, pranoprofen, suprofen, and pharmaceutically acceptable salts, derivatives, and combinations thereof.
  • the active ingredient is an analgesic selected from acetaminophen, acetyl salicylic acid, ibuprofen, naproxen, ketoprofen, flurbiprofen, diclofenac, cyclobenzaprine, meloxicam, rofecoxib, celecoxib, and pharmaceutically acceptable salts, esters, isomers, and mixtures thereof.
  • analgesic selected from acetaminophen, acetyl salicylic acid, ibuprofen, naproxen, ketoprofen, flurbiprofen, diclofenac, cyclobenzaprine, meloxicam, rofecoxib, celecoxib, and pharmaceutically acceptable salts, esters, isomers, and mixtures thereof.
  • the active ingredient is a respiratory agent selected from pseudoephedrine, phenylpropanolamine, chlorpheniramine, dextromethorphan, diphenhydramine, astemizole, terfenadine, fexofenadine, loratadine, cetirizine, mixtures thereof and pharmaceutically acceptable salts, esters, isomers, and mixtures thereof.
  • a respiratory agent selected from pseudoephedrine, phenylpropanolamine, chlorpheniramine, dextromethorphan, diphenhydramine, astemizole, terfenadine, fexofenadine, loratadine, cetirizine, mixtures thereof and pharmaceutically acceptable salts, esters, isomers, and mixtures thereof.
  • Examples of particular active ingredients that may be used in the invention include, but are not limited to: acetaminophen; acetic acid; acetylsalicylic acid, including its buffered forms; acrivastine; albuterol and its sulfate; alcohol; alkaline phosphatase; allantoin; aloe; aluminum acetate, carbonate, chlorohydrate and hydroxide; alprozolam; amino acids; aminobenzoic acid; amoxicillin; ampicillin; amsacrine; amsalog; anethole; ascorbic acid; aspartame; astemizole; atenolol; azatidine and its maleate; bacitracin; balsam peru; BCNU (carmustine); beclomethasone diproprionate; benzocaine; benzoic acid; benzophenones; benzoyl peroxide; benzquinamide and its hydrochloride; bethanechol; biotin; bisacody
  • Active ingredients may further include, but are not limited to food acids; insoluble metal and mineral hydroxides, carbonates, oxides, polycarbophils, and salts thereof; adsorbates of active drugs on a magnesium trisilicate base and on a magnesium aluminum silicate base, and mixtures thereof. Mixtures and pharmaceutically acceptable salts of these and other actives can be used.
  • the amount of active ingredient to be used in the substrate will depend upon several factors such as, for example, the desired active ingredient and the desired dosing requirements, and can be readily determined by one skilled in the art without undue experimentation.
  • Substrates suitable for use in the present invention typically include those suitable for administration as a soft dosage form, i.e. those having a hardness value that permits comfortable chewing and dissolving in the mouth.
  • the hardness of the untreated soft dosage form is no more than about 15 kiloponds per square centimeter (kp/cm 2 ), e.g., from about 1 kp/cm 2 to about 8 kp/cm 2 , or from about 1 kp/cm 2 to about 5 kp/cm 2 .
  • Soft dosage forms having such low hardness values often possess a friability of more than about 2% when measured using the rotating drop method specified by the United States Pharmacopoeia 23, Chapter ⁇ 1216>, p. 1981 (1995), which is incorporated by reference herein.
  • the substrates may be made in any manner, and for tablet dosage forms, a variety of tableting methods are known in the art.
  • Conventional methods for tablet production include direct compression (“dry blending”), dry granulation followed by compression (i.e. compaction), and wet granulation followed by drying and compression (i.e. compaction).
  • Other methods include the use of compacting roller technology such as a chilsonator or drop roller, or molding, casting, or extrusion technologies. All of these methods are well known in the art, and are described in detail in, for example, Lachman, et al., The Theory and Practice of Industrial Pharmacy , Chapter 11, (3 Ed. 1986), which is incorporated by reference herein.
  • a blend of the active ingredient and any other appropriate optional ingredients are directly compacted.
  • a pre-determined volume of particles from the blend is filled into a die cavity of a rotary tablet press, which continuously rotates as part of a “die table” from the filling position to a compaction position to an ejection position.
  • the particles are compacted between an upper punch and a lower punch.
  • the resulting tablet is pushed from the die cavity by the lower punch and guided to an ejection chute by a stationary “take-off” bar.
  • Soft substrates suitable for use in the present invention may be produced via methods known in the art such as, for example, molding or compaction.
  • soft tablets may also be made by direct compaction of a mixture of tableting ingredients, including an active ingredient, and various excipients, such as binders, flavorants, lubricants, etc.
  • the mixture is fed into a die cavity of a tablet press and a tablet is formed by applying pressure.
  • the hardness of the resulting soft tablet is a direct function of the compaction pressure employed and the compactability of the ingredients in the formulation, and is typically up to about 15 kiloponds per square centimeter (kp/cm 2 .
  • the compressed, chewable tablet may be prepared by dry blending the active ingredient, a water-disintegratable, compressible carbohydrate such as, for example, lactose, sorbitol and/or sucrose, and other optional ingredients, then compressing the mixture into the desired shape of a dosage form having a hardness of about 1 kp/cm 2 .
  • a water-disintegratable, compressible carbohydrate such as, for example, lactose, sorbitol and/or sucrose
  • the active ingredient may be coated with a known taste masking coating.
  • suitable taste masking coatings, and methods for their production are described in U.S. Pat. Nos. 4,851,226, 5,075,114, and 5,489,436, which are all incorporated by reference herein.
  • Other commercially available taste masked active ingredients may also be employed.
  • acetaminophen particles which are encapsulated with ethylcellulose or other polymers by a coaccervation process may be used in the present invention.
  • Such coaccervation-encapsulated acetaminophen may be purchased commercially from Eurand America, Inc. Vandalia, Ohio, or from Circa Inc., Dayton, Ohio.
  • a portion of the exterior surface of the substrates is treated with a polymeric dispersion.
  • the polymeric dispersion suitable for use in the present invention is comprised of, based upon the total weight percent of the dispersion, from more than about 0% to about 25%, for example, from greater than about 0% to about 10%, from greater than about 0% to about 5%, or from greater than about 0% to about 2%, of a dispersible polymer, and from about 75% to about less than 100% of a solvent.
  • Dispersible polymers suitable for use in the present invention include, but are not limited to film forming polymers, gelling polymers, adhesive polymers, and derivatives, copolymers, and mixtures thereof.
  • the dispersible polymers are water soluble.
  • the dispersible polymers are also suitable for immediate release dosage forms, which means that the dissolution of one or more active ingredients contained in dosage form conforms to USP specifications for immediate release tablets containing the particular active ingredient employed.
  • suitable film forming polymers include, but are not limited to, polyvinylalcohol (PVA), hydroxypropyl starch, hydroxyethyl starch, pullulan, methylethyl starch, carboxymethyl starch, methylcellulose, hydroxypropylcellulose (HPC), hydroxyethylmethylcellulose (HEMC), hydroxypropylmethylcellulose (HPMC), hydroxybutylmethylcellulose (HBMC), hydroxyethylethylcellulose (HEEC), hydroxyethylhydroxypropylmethyl cellulose (HEMPMC), methacrylic acid copolymers, methacrylate ester copolymers, polyvinyl alcohol and polyethylene glycol copolymers, proteins such as whey protein, egg albumin, casein, casein isolates, soy protein and soy protein isolates, pre-gelatinized starches, corn syrup solids, film-forming modified starches, and copolymers, derivatives and mixtures thereof.
  • PVA polyvinylalcohol
  • HPMC 2910 is a cellulose ether having a degree of substitution of about 1.9 and a hydroxypropyl molar substitution of 0.23, and containing, based upon the total weight of the compound, from about 29% to about 30% methoxyl and from about 7% to about 12% hydroxylpropyl groups.
  • degree of substitution shall mean the average number of substituent groups attached to an anhydroglucose ring
  • hydroxypropyl molar substitution shall mean the number of moles of hydroxypropyl per mole anhydroglucose.
  • HPMC 2910 is commercially available from the Dow Chemical Company under the tradename, “Methocel E.”
  • Methodhocel E5 which is one grade of HPMC-2910 suitable for use in the present invention, has a viscosity of about 4 to 6 cps (4 to 6 millipascal-seconds) at 20° C. in a 2% aqueous solution as determined by a Ubbelohde viscometer.
  • Methodhocel E6 which is another grade of HPMC-2910 suitable for use in the present invention, has a viscosity of about 5 to 7 cps (5 to 7 millipascal-seconds) at 20° C. in a 2% aqueous solution as determined by a Ubbelohde viscometer.
  • Method E15 which is another grade of HPMC-2910 suitable for use in the present invention, has a viscosity of about 15000 cps (15 millipascal-seconds) at 20° C. in a 2% aqueous solution as determined by a Ubbelohde viscometer.
  • One suitable polyvinyl alcohol and polyethylene glycol copolymer is commercially available from BASF Corporation under the tradename “Kollicoat IR”.
  • modified starches include starches that have been modified via crosslinking and/or other chemical modification for improved stability or optimized performance, or physical modification for improved solubility properties or optimized performance.
  • chemically-modified starches are well known in the art and typically include those starches that have been chemically treated to cause replacement of some of its hydroxyl groups with either ester or ether groups.
  • Crosslinking as used herein, may occur in modified starches when two hydroxyl groups on neighboring starch molecules are chemically linked.
  • pre-gelatinized starches or “instantized starches” refers to physically modified starches that have been pre-wetted, then dried to enhance their cold-water solubility. Suitable modified starches are commercially available from several suppliers such as, for example, A.E. Staley Manufacturing Company, and National Starch & Chemical Company.
  • a suitable film forming modified starch includes the pre-gelatinized waxy maize derivative starches that are commercially available from National Starch & Chemical Company under the tradenames, “Purity Gum” and “FilmSet”, and derivatives, copolymers, and mixtures thereof.
  • waxy maize starches typically contain, based upon the total weight of the starch, from about 0 percent to about 18 percent of amylose and from about 100 percent to about 88 percent of amylopectin.
  • Another suitable film forming modified starch includes the hydroxypropylated starches, in which some of the hydroxyl groups of the starch have been etherified with hydroxypropyl groups, usually via treatment with propylene oxide.
  • a suitable hydroxypropyl starch that possesses film-forming properties is available from Grain Processing Company under the tradename, “Pure-Cote B790”.
  • Suitable film forming tapioca dextrins include those available from National Starch & Chemical Company under the tradename, “Crystal Gum” or “K-4484,” and derivatives thereof such as modified food starch derived from tapioca, which is available from National Starch and Chemical under the tradename, “Purity Gum 40,” and copolymers and mixtures thereof.
  • Another suitable film forming material derived from starch is corn syrup solids, which is commercially available from National Starch and Chemical under the trademark, “N-Tack”; derivatives thereof; copolymers thereof; and mixtures thereof.
  • any gelling polymer known in the art is suitable for use in the present invention.
  • examples of such gelling polymers include but are not limited to hydrocolloids such as alginates, agar, guar gum, locust bean gum, kappa carrageenan, iota carrageenan, tara, gum arabic, tragacanth, pectin, xanthan gum, gellan gum, maltodextrin, galactomannan, pusstulan, laminarin, scleroglucan, gum arabic, inulin, pectin, whelan, rhamsan, zooglan, methylan, chitin, chitosan; gelling starches such as acid hydrolyzed starches and derivatives and mixtures thereof.
  • Suitable xanthan gums include those available from C.P. Kelco Company under the tradename, “Keltrol 1000,” “Xantrol 180,” or “K9B310.”
  • Gelling starches include those starches that, when combined with water and heated to a temperature sufficient to form a solution, thereafter form a gel upon cooling to a temperature below the gelation point of the starch.
  • Examples of gelling starches include, but are not limited to, acid hydrolyzed starches such as that available from Grain Processing Corporation under the tradename, “Pure-Set B950”; hydroxypropyl distarch phosphate such as that available from Grain Processing Corporation under the tradename, “Pure-Gel B990”, and mixtures thereof.
  • Acid-hydrolyzed starch is one type of modified starch that results from treating a starch suspension with dilute acid at a temperature below the gelatinization point of the starch. During the acid hydrolysis, the granular form of the starch is maintained in the starch suspension, and the hydrolysis reaction is ended by neutralization, filtration and drying once the desired degree of hydrolysis is reached. As a result, the average molecular size of the starch polymers is reduced. Acid-hydrolyzed starches (also known as “thin boiling starches”) tend to have a much lower hot viscosity than the same native starch as well as a strong tendency to gel when cooled.
  • any adhesive polymer known in the art is suitable for use in the present invention.
  • adhesive polymers include, but are not limited to, polysaccharides such as maltodextrin, polydextrose, and mucilagee; proteins such as gelatin, whey protein, and albumin, and derivatives and combinations thereof.
  • solvents suitable for use in the present invention include, but are not limited to, water; water-miscible polar organic solvents such as methanol, ethanol, isopropanol, and acetone; non-water miscible organic solvents such as methylene chloride, methylethylketone, methylisobutylketone, chloraform, benzene, toluene, pentane, and hexane; and derivatives and mixtures thereof.
  • water-miscible polar organic solvents such as methanol, ethanol, isopropanol, and acetone
  • non-water miscible organic solvents such as methylene chloride, methylethylketone, methylisobutylketone, chloraform, benzene, toluene, pentane, and hexane
  • solvents suitable for use in the present invention include, but are not limited to, water; water-miscible polar organic solvents such as
  • the polymer dispersion is substantially free of adjuvants or modifiers such as plasticizers, dispersion aids, welting agents, stabilizers, preservatives, and the like.
  • substantially free it is meant that the polymer dispersion contains, based upon the total weight of the polymer dispersion, less than about 5%, e.g. less than about 1% of adjuvants or modifiers.
  • the polymeric dispersion may be prepared by dispersing the dispersable polymer in the solvent under suitable conditions to uniformly disperse the polymer at the molecular level.
  • the solvent is water
  • the polymeric dispersion may be prepared by heating water to a temperature effective for solubilizing the polymer.
  • the temperature and quantity of water may depend on, for example, the solubility of the polymer selected, typically the required temperature may range from about room temperature to about 90° C.
  • the dispersible polymer may then be added to the heated water, with stirring, until all of the polymer is dissolved therein.
  • the resulting solution is cooled to ambient temperature and, if necessary, further diluted with an additional amount of room temperature water in order to achieve the desired solution concentration.
  • the polymeric dispersion of the present invention may be applied to various types of substrates, especially those that are soft and/or are highly friable.
  • substrates especially those that are soft and/or are highly friable.
  • treated substrates may nonexclusively result products such as pharmaceutical dosage forms, confectionary products, nutritional supplements, food stuffs, dyestuffs, and dietary supplements
  • an effective amount of the polymeric dispersion of the present invention may be applied to the surface of the substrate such that the overall friability of the treated substrate is reduced by a factor of at least about 2, e.g. at least about 2.5, at least about 3, or at least about 5, relative to the friability of the uncoated substrate.
  • a reduction in friability may be achieved by applying the composition of the present invention to at least a portion of a vulnerable edge such that less than all of the exterior substrate surface, e.g. from about 10% to about 90%, from about 20% to about 80% or from about 20% to about 50% of the exterior substrate surface, has been treated with the polymeric dispersion.
  • the polymeric dispersion is primarily applied to at least a portion of: 1) one or more of the rims; 2) the belly band; 3) one or more of the face(s); 4) and/or one or more of the land(s), with the remainder of the substrate having no polymeric dispersion applied thereto.
  • FIGS. 7A through 7E The areas of a flat, disk-shaped tablet onto which a polymeric dispersion may be applied are illustrated in FIGS. 7A through 7E, and further explained in Table A below: TABLE A Areas For Polymeric Dispersion Application FIGURE AREAS NUMBER ON TABLET TO WHICH DISPERSION IS APPLIED 7A Two faces (including two rims) 7B Belly band (including two rims) 7C Two faces (including one-half of a rim/face) 7D Belly band (including one-half of an upper rim and one-half of a lower rim) 7E Two rims
  • the resulting treatment area includes both that vulnerable edge as well as an overlap area.
  • the quantity of substrate surface area receiving treatment may be approximated by relating about 1 linear millimeter of vulnerable edge to about 2 square millimeters of treated substrate surface. See, for example, FIG. 2, which exemplifies that treatment of the rim includes an overlap area 15 .
  • substrates that do not bear substantial opposing planar surfaces such as, for example, the biconvex shape of FIG.
  • the polymeric dispersion may be applied on the upper land 43 ′ and/or the lower land 43 ′′ in a similar fashion such that an effective amount of the dispersion enrobes and includes one-half of the upper rim 41 ′ and/or one-half of the lower rim 41 ′′, respectively, in an overlap area 115 .
  • the location and size of the substrate surface area on which the polymeric dispersion treatment is applied may vary depending upon, for example, the nature of the substrate surface, the thickness of the polymeric dispersion application, the shape of the substrate, and the dimensions of the substrate.
  • the quantity of polymeric dispersion applied to the substrate will depend upon a number of factors including, but not limited to, the concentration of the polymer in the dispersion, the desired thickness of the application on the substrate, the hardness of the substrate surface, and the dimension of the substrate surfaces.
  • the polymeric dispersion should be applied to at least one treatment surface location such that the substrate possesses a polymer layer of from about 3 micrograms/mm 2 to about 20 micrograms/mm 2 , e.g. from about 4 micrograms/mm 2 to about 12 micrograms/mm 2 or from about 5 micrograms/mm 2 to about 9 micrograms/mm 2 .
  • composition of the present invention may be applied to a substrate by any method well known in the art. Such methods may include, but are not limited to, the use of a wet roller, a brush, or a spray nozzle, and are disclosed in, for example, U.S. Pat. No. 5,922,342, which is incorporated by reference herein
  • the substrate may be removably secured to a rotation means, and the polymeric dispersion may then be applied to the desired treatment surface location on the rotating substrate.
  • the temperature and pressure conditions for applying the polymeric dispersion to the substrate will vary dependent upon several factors such as, for example, the type of polymers selected, in general the temperature may range from about 20° C. to about 90° C., e.g. from about 25° C. to 65° C.
  • the polymeric dispersion is generally applied to the substrate at a temperature of less than about 90° C. because HPMC is not soluble in water at higher temperatures.
  • the treated substrate may then be dried in order to evaporate the solvent from the composition and to set the polymer.
  • the desired drying temperature and setting time may vary depending upon, for example, the type of polymer selected, the solvent employed, and the concentration of polymeric dispersion employed, and would readily be appreciated by one having ordinary skill in the art without undue experimentation.
  • the treated substrate produced in accordance with the present invention possesses a polymeric layer that is in contact with the treatable surface of the substrate.
  • “in contact with” shall mean that the layer resides upon, and/or resides at, and/or resides immediately beneath, at least a portion of the treatable surface, and “immediately beneath,” as used herein shall mean within a location that is less than about 2 mm inwards from the treatable surface.
  • the polymeric dispersion may penetrate the treatable surface to the extent that the formed polymer layer both resides immediately beneath the treatable surface as well as at the treatable surface.
  • FIG. 8A represents a cross-sectional view of a substrate 900 possessing a polymeric layer 901 that resides upon at least a portion of the treatable surface 902 .
  • FIG. 8B represents a cross-sectional view of a substrate 900 possessing a polymeric layer 901 residing at a portion of the treatable surface 902 .
  • FIG. 8C is a cross-sectional view of a substrate 900 possessing a polymeric layer 901 immediately beneath at least a portion of the treatable surface 902 .
  • the depth of penetration of the applied polymeric dispersion may depend upon a number of factors such as, for example, the hardness of the substrate.
  • substrates treated with polymeric dispersions in accordance with the present invention do not incur an increase in hardness that is substantially perceptible to the user.
  • such treated substrates incur a negligible weight gain, i.e., e.g., a post-drying gain of less than about 0.5%.
  • the weight of the water dispersible polymer layer is not more than about 0.5%, e.g. not more than about 0.25%, say not more than about 0.1% of the weight of the untreated substrate.
  • the polymeric dispersion when the polymeric dispersion is applied predominantly to the treatable surfaces, so that from about 10% to about 90% of the overall substrate surface has been treated with the polymeric dispersion of the present invention, the overall friability of the substrate is reduced by a factor of at least about 2. Because a consumer would not perceive the addition of the small quantity of composition thereto, this reduction in friability occurs without a sacrifice in organoleptic characteristics, such as mouthfeel.
  • the tablets of the present invention posses a fast melt-away charasteric because their disintegration and dissolution in the oral cavity are not hindered by the presence of a coating.
  • Another substantial advantage of this invention is that it permits low hardness substrates to be subsequently coated with one or more additional coatings (e.g. film-coatings) using processes that may have otherwise destroyed the integrity of such substrates but for the treatment in accordance with the present invention.
  • additional coatings e.g. film-coatings
  • a surface treatment solution having the components set forth below was prepared as follows: Coating solution ingredients: Deionized water 100 mL HPMC* 5.0 g
  • a round, flat-faced, beveled edge tablet which was commercially available from McNEIL-PPC, Inc. under the tradename, “MOTRIN Jr. Strength,” was selected from a batch with an average hardness value of 2.57 kp/cm 2 .
  • the tablet which had a height of approximately 5.56 mm and a radius of approximately 12 mm, weighed about 770 mg.
  • the tablet was fixed to a 1 ⁇ 4 inch wooden dowel attached to an inverted mixer (Model RW-20 DZM, Janke&Kunkel, IKA-Works, Inc.) with a small quantity of mounting putty (Manco Inc.). The mixer was set to rotate the dowel and substrate at approximately 30 rpm.
  • Example 2 The procedure set forth in Example 2 was independently repeated on 10 tablets, but with treatment of the belly band as opposed to the rim of each tablet.
  • Example 2 The procedure set forth in Example 2 was independently repeated on 10 tablets, but with treatment of both opposing faces as opposed to the rim of each tablet.
  • This Example demonstrated that treating a soft substrate with the composition of the present invention at predominantly only the rim of the substrate surface substantially improved the friability of the treated tablets.
  • this Example showed that the friability of tablets, which were treated only along the rim, was significantly lower that that of the tablets which were treated on both faces.
  • a surface treatment solution having the components set forth below was prepared as follows: Coating solution ingredients: Deionized water 100 mL N-Tack Starch* 25.0 g
  • Example 1 The polymeric dispersion of Example 1 was applied to 15 untreated tablets of Example 2 ( ⁇ fraction (15/32) ⁇ ′′ diameter, 5.56 mm height) in accordance with the procedure set forth in Examples 2-4.
  • the polymeric dispersion (6.7 ⁇ g per mm 2 of surface treated) was applied to one of the treatment surfaces identified in FIG. 7A through FIG. 7E.
  • the treated surface area which was expressed in terms of the percentage of total substrate surface area that was treated with the polymeric dispersion, was measured. This procedure is repeated for the tablets having a 1 ⁇ 4′′ diameter and a 3 ⁇ 4′′ diameter, respectively.
  • Table C shows the measured results for the treated tablets: TABLE C Treated Surface Area in terms of Total Tablet Surface Area Tablet w/1 ⁇ 4′′ Tablet w/ ⁇ fraction (15/32) ⁇ ′′ diameter, diameter, Tablet w/3 ⁇ 4′′ 2.8 mm 5.56 mm diameter, 9 mm Treatment Surface height height height Both faces (FIG. 7A) 86.6% 66.2% 61.4% Belly Band and both 76.4% 64.2% 60.0% rims* (FIG. 7B) Both faces, 1 ⁇ 2 upper 52.3% 51.7% 50.4% rim and 1 ⁇ 2 lower rim (FIG. 7C) Bellyband, 1 ⁇ 2 upper 47.7% 48.3% 49.6% rim and 1 ⁇ 2 lower rim (FIG. 7D) Both rims (FIG. 7E) 63.0% 30.4% 21.4%
  • Ibuprofen particles coated with a mixture of hydroxyethylcellulose and hydroxypropylmethylcellulose, according to the method disclosed in U.S. Pat. No. 5,320,855 were blended with aspartame, prosweet powder, citric acid, granular mannitol, microcrystalline cellulose, flavor and color in a plastic bag by inverting about 100 times. After magnesium stearate was added thereto, the mixture was further blended by inverting about 20 times.
  • the components of the resulting blend are set forth in Table C below: TABLE C Components of Chewable Blend Amount Used Component Name (mg/tablet) Encapsulated Ibuprofen 131.14 (76.25%) Aspartame** 10.82 Prosweet Powder No. 694* 2.54 Citric Acid** 4.26 Mannitol** 528.10 Microcrystalline cellulose*** 84.10 FD&C Yellow No. 6 Aluminum 1.76 Lake Orange flavor** 1.76 Magnesium stearate** 5.52 TOTAL 770
  • This Example showed that the friability of the treated substrates was significantly reduced by applying the polymeric dispersion to only a portion of the substrate surface.
  • the effectiveness of the treatment depends on the water dispersible polymer employed, the substrate hardness, and the location of treatment surface. For example, the largest friability factors (most reduction in friability) were obtained by applying a 5% HPMC dispersion to both faces of the hardest tablet, and by applying a 25% corn syrup solids dispersion to both faces of the softest tablet.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Application Of Or Painting With Fluid Materials (AREA)
  • Paints Or Removers (AREA)
  • Coating Of Shaped Articles Made Of Macromolecular Substances (AREA)
US10/309,730 2002-12-04 2002-12-04 Surface treatment composition for soft substrates Abandoned US20040109889A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
US10/309,730 US20040109889A1 (en) 2002-12-04 2002-12-04 Surface treatment composition for soft substrates
EP03257620A EP1426042A1 (en) 2002-12-04 2003-12-03 Surface treatment composition for soft substrates
CA2452074A CA2452074C (en) 2002-12-04 2003-12-03 Surface treatment composition for soft substrates
BR0305412-8A BR0305412A (pt) 2002-12-04 2003-12-04 Composição de tratamento de superfìcie para substratos macios
MXPA03011173A MXPA03011173A (es) 2002-12-04 2003-12-04 Composicion de tratamiento de superficie substratos blandos.
ARP030104476A AR042299A1 (es) 2002-12-04 2003-12-04 Composicion de tratamiento de superficie para substratos blandos
US12/370,117 US8173161B2 (en) 2002-12-04 2009-02-12 Method of administering a pharmaceutical active ingredient

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/309,730 US20040109889A1 (en) 2002-12-04 2002-12-04 Surface treatment composition for soft substrates

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/370,117 Continuation US8173161B2 (en) 2002-12-04 2009-02-12 Method of administering a pharmaceutical active ingredient

Publications (1)

Publication Number Publication Date
US20040109889A1 true US20040109889A1 (en) 2004-06-10

Family

ID=32312246

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/309,730 Abandoned US20040109889A1 (en) 2002-12-04 2002-12-04 Surface treatment composition for soft substrates
US12/370,117 Expired - Fee Related US8173161B2 (en) 2002-12-04 2009-02-12 Method of administering a pharmaceutical active ingredient

Family Applications After (1)

Application Number Title Priority Date Filing Date
US12/370,117 Expired - Fee Related US8173161B2 (en) 2002-12-04 2009-02-12 Method of administering a pharmaceutical active ingredient

Country Status (6)

Country Link
US (2) US20040109889A1 (es)
EP (1) EP1426042A1 (es)
AR (1) AR042299A1 (es)
BR (1) BR0305412A (es)
CA (1) CA2452074C (es)
MX (1) MXPA03011173A (es)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060087051A1 (en) * 2004-10-27 2006-04-27 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US20060088586A1 (en) * 2004-10-27 2006-04-27 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US20060088585A1 (en) * 2004-10-27 2006-04-27 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US20060088593A1 (en) * 2004-10-27 2006-04-27 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US20060088587A1 (en) * 2004-10-27 2006-04-27 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US20070190133A1 (en) * 2004-10-27 2007-08-16 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US20070281022A1 (en) * 2004-10-27 2007-12-06 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US8637540B2 (en) 2003-11-26 2014-01-28 Acura Pharmaceuticals Compositions for deterring abuse of opioid containing dosage forms
US8901113B2 (en) 2009-09-30 2014-12-02 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
US9101636B2 (en) 2012-11-30 2015-08-11 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
US9616029B2 (en) 2014-03-26 2017-04-11 Sun Pharma Advanced Research Company Ltd. Abuse deterrent immediate release coated reservoir solid dosage form
US10117831B2 (en) 2015-12-19 2018-11-06 First Time Us Generics Llc Soft chew pharmaceutical formulations
US11103581B2 (en) 2015-08-31 2021-08-31 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
US11633361B2 (en) 2015-12-19 2023-04-25 First Time Us Generics Llc Soft chew pharmaceutical formulations

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2651399A2 (en) 2010-12-13 2013-10-23 Purdue Pharma LP Controlled release dosage forms
JP6379884B2 (ja) * 2014-09-03 2018-08-29 ニプロ株式会社 口腔内崩壊錠、及び口腔内崩壊錠の製造方法
WO2017151571A1 (en) * 2016-02-29 2017-09-08 First Time Us Generics Llc Abuse deterrent soft chewable drug formulations
USD845541S1 (en) * 2016-04-05 2019-04-09 Budich International Gmbh Blocks of washing products
USD789514S1 (en) 2016-06-01 2017-06-13 David Hill Injectable tablet

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4820524A (en) * 1987-02-20 1989-04-11 Mcneilab, Inc. Gelatin coated caplets and process for making same
US4839177A (en) * 1985-12-20 1989-06-13 Jagotec Ag System for the controlled-rate release of active substances
US5178878A (en) * 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles
US5837284A (en) * 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US5888534A (en) * 1995-06-13 1999-03-30 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
US6210710B1 (en) * 1997-04-28 2001-04-03 Hercules Incorporated Sustained release polymer blend for pharmaceutical applications
US6274162B1 (en) * 2000-01-14 2001-08-14 Bpsi Holdings, Inc. Elegant film coating system
US6277409B1 (en) * 2000-02-11 2001-08-21 Mcneil-Ppc, Inc. Protective coating for tablet
US20010034374A1 (en) * 2000-05-01 2001-10-25 Adjei Akwete L. Core formulation
US20030124183A1 (en) * 2001-09-28 2003-07-03 Sowden Harry S. Systems, methods and apparatuses for manufacturing dosage forms
US6713089B1 (en) * 1998-09-10 2004-03-30 Nycomed Danmark A/S Quick release pharmaceutical compositions of drug substances

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB972128A (en) 1960-01-21 1964-10-07 Wellcome Found Pellets for supplying biologically active substances to ruminants and the manufacture of such pellets
US3851638A (en) 1973-02-02 1974-12-03 Kam Act Enterprises Inc Force multiplying type archery bow
US4209513A (en) 1974-02-14 1980-06-24 Burroughs Wellcome Co. Tablet formulation
GB1533243A (en) 1975-02-13 1978-11-22 Wellcome Found Tablet formulation
US4327076A (en) 1980-11-17 1982-04-27 Life Savers, Inc. Compressed chewable antacid tablet and method for forming same
US4395422A (en) 1981-04-06 1983-07-26 Basf Wyandotte Corporation Spray dried vitamin E powder
EP0070127A3 (en) 1981-07-10 1983-08-17 Beecham Group Plc Tablets
US4562024A (en) 1982-07-06 1985-12-31 Sterling Drug Inc. Process for preparing granulate containing poorly compressible medicinally active matter
DE3245170A1 (de) 1982-12-07 1984-06-07 Merck Patent Gmbh, 6100 Darmstadt Verbesserter sorbit, verfahren zur herstellung und verwendung
US4533674A (en) 1983-10-24 1985-08-06 Basf Wyandotte Corporation Process for preparing a sugar and starch free spray-dried vitamin C powder containing 90 percent ascorbic acid
CA1229552A (en) 1984-07-09 1987-11-24 Audley A. Legore Cimetidine compositions
FR2571045B1 (fr) 1984-10-03 1987-12-11 Roquette Freres Mannitol granulaire directement compressible et son procede de fabrication
US4631284A (en) 1984-11-19 1986-12-23 Mallinckrodt, Inc. Acetaminophen compositions containing low doses of chlorpheniramine maleate, method for preparing same and tablets formed therefrom
PL149493B1 (en) 1985-04-12 1990-02-28 Method of obtaining a tablet capable to buoy over surface of gastric juice
US4663147A (en) 1985-09-03 1987-05-05 International Minerals & Chemical Corp. Disc-like sustained release formulation
US4710519A (en) 1985-09-30 1987-12-01 Basf Corporation Process for preparing spray dried acetaminophen powder and the powder prepared thereby
IT1187750B (it) 1985-10-15 1987-12-23 Eurand Spa Procedimento per la preparazione di compresse,anche a rilascio prolungato,di iscsorbide-5-mononitrato stabilizzato e formulazioni cosi' ottenute
US4816262A (en) 1986-08-28 1989-03-28 Universite De Montreal Controlled release tablet
US4803076A (en) 1986-09-04 1989-02-07 Pfizer Inc. Controlled release device for an active substance
YU47044B (sh) 1987-03-11 1994-12-28 LEK TOVARNA FARMACEVTSKIH IN KEMIČNIH IZDELKOV n.sol.o. Postupak za dobijanje tableta sa produženim delovanjem na bazi hidroksipropil-metilceluloze velike molekularne mase
US4904477A (en) 1987-07-08 1990-02-27 American Home Products Corporation Spray dried ibuprofen compositions
US4851226A (en) 1987-11-16 1989-07-25 Mcneil Consumer Products Company Chewable medicament tablet containing means for taste masking
US4906478A (en) 1988-12-12 1990-03-06 Valentine Enterprises, Inc. Simethicone/calcium silicate composition
US5104648A (en) 1989-02-02 1992-04-14 Mallinckrodt Specialty Chemicals Company High ibuprofen content granulations
US5223264A (en) 1989-10-02 1993-06-29 Cima Labs, Inc. Pediatric effervescent dosage form
US4983399A (en) 1989-10-18 1991-01-08 Eastman Kodak Company Direct compression carrier composition
US5275822A (en) 1989-10-19 1994-01-04 Valentine Enterprises, Inc. Defoaming composition
IT1237904B (it) * 1989-12-14 1993-06-18 Ubaldo Conte Compresse a rilascio a velocita' controllata delle sostanze attive
US5075114A (en) 1990-05-23 1991-12-24 Mcneil-Ppc, Inc. Taste masking and sustained release coatings for pharmaceuticals
RU2039553C1 (ru) 1990-08-03 1995-07-20 Аста Медика, АГ Твердая лекарственная форма ифосфамида
US5922342A (en) 1990-10-01 1999-07-13 Pharmacia & Upjohn Company Lateral edge coated controlled release pharmaceutical compositions
EP0487774B1 (en) 1990-11-29 1994-10-26 Wei Ming Pharmaceutical Mfg. Co. Ltd. A direct tabletting auxiliary
US5204115A (en) 1990-12-12 1993-04-20 Suomen Xyrofin Oy Directly compressible xylitol and method
EP0522128B1 (en) * 1991-01-30 1996-01-17 The Wellcome Foundation Limited Water-dispersible tablets
ATE245023T1 (de) 1991-05-28 2003-08-15 Mcneil Ppc Inc Kaubare zusammensetzung zur arzneimittelfreisetzung
CA2068402C (en) 1991-06-14 1998-09-22 Michael R. Hoy Taste mask coatings for preparation of chewable pharmaceutical tablets
US5217965A (en) 1991-06-17 1993-06-08 Euroceltique, S.A. Stabilized solid dosage forms of choline metal carboxymethylcellulose salicylate compositions
CZ286958B6 (cs) 1991-07-03 2000-08-16 Pharmacia & Upjohn Company Tabletování lékových směsí hydrochloridu colestipolu
US5464632C1 (en) 1991-07-22 2001-02-20 Prographarm Lab Rapidly disintegratable multiparticular tablet
US5262171A (en) 1991-11-25 1993-11-16 Isp Investments Inc. Pharmaceutical tablet with PVP having enhanced drug dissolution rate
ES2096103T3 (es) 1992-01-13 1997-03-01 Pfizer Preparacion de comprimidos de resistencia incrementada.
US5616344A (en) 1994-06-14 1997-04-01 Fuisz Technologies Ltd. Apparatus and process for strengthening low density compression dosage units and product therefrom
FR2710637B1 (fr) 1993-09-28 1995-12-08 Roquette Freres Mannitol pulvérulent de friabilité modérée et son procédé de préparation.
IT1270239B (it) 1994-06-17 1997-04-29 Zambon Spa Composizione farmaceutica solida contenente acido (s)-2-(4- isobutilfenil) propionico come principio attivo
GB9501127D0 (en) 1995-01-20 1995-03-08 Wellcome Found Tablet
US5674529A (en) 1995-06-06 1997-10-07 Church & Dwight Co., Inc. Alkalinizing potassium salt controlled release preparations
SE513815C2 (sv) 1995-08-25 2000-11-06 Wasa Medicals Ab Förfarande för framställning av tabletter innehållande levande mikroorganismer och med oligosacharider i tablettmaterialet
GB2305604B (en) 1995-09-29 1999-06-23 Quest Vitamins Ltd Carrier base material
JP4064476B2 (ja) 1996-03-29 2008-03-19 エラワン ファーマスーティカル リサーチ アンドラボラトリー カンパニー リミテッド 二酸化珪素を有する球状凝集した澱粉
US5858409A (en) 1996-04-17 1999-01-12 Fmc Corporation Hydrolyzed cellulose granulations for pharmaceuticals
TR199802616T2 (xx) 1996-06-17 1999-03-22 Janssen Pharmaceutica N.V. �ift-konveks, h�zl� par�alanan dozaj formlar�.
US5846568A (en) 1996-09-19 1998-12-08 Xyrofin Oy Directly compressible lactitol and method
JP2001503766A (ja) 1996-11-12 2001-03-21 フアーマシア・アンド・アツプジヨン・アー・ベー 複数の多孔質セルロースマトリクス（ｐｃｍ）を含むコンパクト部材、その製造および使用方法
US6024981A (en) 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
US6103260A (en) 1997-07-17 2000-08-15 Mcneil-Ppc, Inc. Simethicone/anhydrous calcium phosphate compositions
GB9716432D0 (en) 1997-08-05 1997-10-08 Cerestar Holding Bv Tableting of erythritol
FI109088B (fi) 1997-09-19 2002-05-31 Leiras Oy Tabletti ja menetelmä sen valmistamiseksi
AU9432498A (en) 1997-10-02 1999-04-27 H. Lundbeck A/S Granular preparations of 5-(2-ethyl- 2(h)-tetrazol- 5-yl)-1-methyl-1, 2,3,6-tetrahydropyridine
ES2169558T3 (es) 1997-10-03 2002-07-01 Warner Lambert Co Pastilla de nitroglicerina comprimida y metodo para su produccion.
WO1999018937A1 (en) 1997-10-16 1999-04-22 Merck & Co., Inc. New cyclobenzaprine composition
US5955107A (en) 1997-12-12 1999-09-21 Fmc Corporation Pharmaceutical suspension tablet compositions
DE19758100B4 (de) 1997-12-18 2006-05-04 Lichtwer Pharma Ag Verfahren zum Herstellen von Pflanzenextrakt enthaltenden pharmazeutischen Formulierungen
CN100379407C (zh) 1997-12-19 2008-04-09 史密丝克莱恩比彻姆公司 生产咀嚼分散片的方法
GB9802201D0 (en) 1998-02-03 1998-04-01 Cerestar Holding Bv Free-flowable directly compressible starch as binder,disintegrant and filler for compresion tablets and hard gelatine capsules
US6110500A (en) 1998-03-25 2000-08-29 Temple University Coated tablet with long term parabolic and zero-order release kinetics
US6270790B1 (en) * 1998-08-18 2001-08-07 Mxneil-Ppc, Inc. Soft, convex shaped chewable tablets having reduced friability
FR2790387B1 (fr) * 1999-03-01 2001-05-18 Prographarm Laboratoires Comprime orodispersible presentant une faible friabilite et son procede de preparation
US6258381B1 (en) 2000-02-11 2001-07-10 Mcneil-Ppc, Inc. Tablet and process for making the same
GB0117619D0 (en) * 2001-07-19 2001-09-12 Phoqus Ltd Pharmaceutical dosage form
GB0204772D0 (en) * 2002-02-28 2002-04-17 Phoqus Ltd Pharmaceutical dosage forms

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4839177A (en) * 1985-12-20 1989-06-13 Jagotec Ag System for the controlled-rate release of active substances
US4820524A (en) * 1987-02-20 1989-04-11 Mcneilab, Inc. Gelatin coated caplets and process for making same
US5178878A (en) * 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles
US5888534A (en) * 1995-06-13 1999-03-30 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
US5837284A (en) * 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US6210710B1 (en) * 1997-04-28 2001-04-03 Hercules Incorporated Sustained release polymer blend for pharmaceutical applications
US6713089B1 (en) * 1998-09-10 2004-03-30 Nycomed Danmark A/S Quick release pharmaceutical compositions of drug substances
US6274162B1 (en) * 2000-01-14 2001-08-14 Bpsi Holdings, Inc. Elegant film coating system
US6277409B1 (en) * 2000-02-11 2001-08-21 Mcneil-Ppc, Inc. Protective coating for tablet
US20010034374A1 (en) * 2000-05-01 2001-10-25 Adjei Akwete L. Core formulation
US20030124183A1 (en) * 2001-09-28 2003-07-03 Sowden Harry S. Systems, methods and apparatuses for manufacturing dosage forms

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9492443B2 (en) 2003-11-26 2016-11-15 Acura Pharmaceuticals, Inc. Abuse deterrent compositions and methods of making same
US8637540B2 (en) 2003-11-26 2014-01-28 Acura Pharmaceuticals Compositions for deterring abuse of opioid containing dosage forms
US8822489B2 (en) 2003-11-26 2014-09-02 Acura Pharmaceuticals Abuse deterrent compositions and methods of making same
US20060088586A1 (en) * 2004-10-27 2006-04-27 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US20060088585A1 (en) * 2004-10-27 2006-04-27 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US20060088593A1 (en) * 2004-10-27 2006-04-27 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US20060088587A1 (en) * 2004-10-27 2006-04-27 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US20070190133A1 (en) * 2004-10-27 2007-08-16 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US20070281022A1 (en) * 2004-10-27 2007-12-06 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US8383159B2 (en) 2004-10-27 2013-02-26 Mcneil-Ppc, Inc. Dosage forms having a microreliefed surface and methods and apparatus for their production
US20060087051A1 (en) * 2004-10-27 2006-04-27 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US8901113B2 (en) 2009-09-30 2014-12-02 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
US10155044B2 (en) 2009-09-30 2018-12-18 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
US9320796B2 (en) 2012-11-30 2016-04-26 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
US9101636B2 (en) 2012-11-30 2015-08-11 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
US10441657B2 (en) 2012-11-30 2019-10-15 Abuse Deterrent Pharmaceuticals, Llc Methods and compositions for self-regulated release of active pharmaceutical ingredient
US10688184B2 (en) 2012-11-30 2020-06-23 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
US11857629B2 (en) 2012-11-30 2024-01-02 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
US9616029B2 (en) 2014-03-26 2017-04-11 Sun Pharma Advanced Research Company Ltd. Abuse deterrent immediate release coated reservoir solid dosage form
US9980917B2 (en) 2014-03-26 2018-05-29 Sun Pharma Advanced Research Company Ltd. Abuse deterrent immediate release coated reservoir solid dosage form
US11103581B2 (en) 2015-08-31 2021-08-31 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
US10117831B2 (en) 2015-12-19 2018-11-06 First Time Us Generics Llc Soft chew pharmaceutical formulations
US11633361B2 (en) 2015-12-19 2023-04-25 First Time Us Generics Llc Soft chew pharmaceutical formulations

Also Published As

Publication number Publication date
BR0305412A (pt) 2005-01-18
US8173161B2 (en) 2012-05-08
EP1426042A1 (en) 2004-06-09
MXPA03011173A (es) 2004-09-10
CA2452074C (en) 2012-10-30
CA2452074A1 (en) 2004-06-04
US20090258039A1 (en) 2009-10-15
AR042299A1 (es) 2005-06-15

Similar Documents

Publication Publication Date Title
US8173161B2 (en) Method of administering a pharmaceutical active ingredient
CA2405190C (en) Simethicone solid oral dosage form
US7815937B2 (en) Quick dissolve compositions and tablets based thereon
CA2348451C (en) Dosage forms containing taste masked active agents
US8496969B2 (en) Soft tablet containing high molecular weight cellulosics
US8007825B2 (en) Oral compositions containing a salivation inducing agent
EP2252271B1 (en) Dip coated compositions containing a starch having a high amylose content
US20090104267A1 (en) Soft tablet containing high molecular weight cellulosics
CA2391439C (en) Brittle-coating, soft core dosage form
US20120082729A1 (en) Quick dissolve compositions and tablets based thereon
US20060093560A1 (en) Immediate release film coating
CA2301282A1 (en) Process for improving flow and compression of tableting compositions
CA2472432C (en) Soft tablet containing high molecular weight cellulosics
MX2008004381A (es) Composicion oral que contiene un agente inductor de salivacion

Legal Events

Date Code Title Description
AS Assignment

Owner name: MCNEIL-PPC, INC., NEW JERSEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BUNICK, FRANK J.;LIN, FENG;REEL/FRAME:013446/0715;SIGNING DATES FROM 20021218 TO 20030102

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION